Free tool
FAERS Monitor: Omnipaque 140
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018956 or its brand name (Omnipaque 140, Iohexol). Reports on generic versions are filed under their own applications.
Reports
8,472
Serious
6,838
81% of reports
Hospitalization
2,772
Death reported
503
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- urticaria1,021
- pruritus929
- dyspnoea799
- sneezing630
- erythema586
- nausea538
- vomiting494
- rash430
- chills360
- cough338
- anaphylactic reaction322
- acute kidney injury299
- hypotension282
- contrast media reaction270
- pyrexia266
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 7 |
| 2005 | 10 |
| 2006 | 5 |
| 2007 | 7 |
| 2008 | 11 |
| 2009 | 6 |
| 2010 | 13 |
| 2011 | 17 |
| 2012 | 175 |
| 2013 | 370 |
| 2014 | 699 |
| 2015 | 601 |
| 2016 | 578 |
| 2017 | 697 |
| 2018 | 576 |
| 2019 | 550 |
| 2020 | 577 |
| 2021 | 489 |
| 2022 | 491 |
| 2023 | 542 |
| 2024 | 617 |
| 2025 | 778 |
| 2026 | 656 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,687 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| contrast media reactionSignal | 270 | 320.6 | 283.0 | 75,918 |
| sneezingSignal | 630 | 71.7 | 66.4 | 42,673 |
| urticariaSignal | 1,021 | 15.2 | 14.4 | 13,573 |
| anaphylactic reactionSignal | 322 | 14.5 | 13.1 | 4,036 |
| chillsSignal | 360 | 7.6 | 6.9 | 2,078 |
| erythemaSignal | 586 | 7.1 | 6.6 | 3,083 |
| pruritusSignal | 929 | 6.0 | 5.7 | 3,941 |
| acute kidney injurySignal | 299 | 4.9 | 4.3 | 917 |
| dyspnoeaSignal | 799 | 3.5 | 3.3 | 1,467 |
| hypotensionSignal | 282 | 3.5 | 3.1 | 504 |
| coughSignal | 338 | 3.0 | 2.7 | 453 |
| vomitingSignal | 494 | 2.6 | 2.4 | 500 |
| rashSignal | 430 | 2.5 | 2.2 | 375 |
| pyrexia | 266 | 1.9 | 1.7 | 116 |
| nausea | 538 | 1.7 | 1.6 | 156 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.